BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present at the 14th Annual RNA Consortium Meeting.

Tauriga Sciences, Inc., a New York based diversified Life Sciences Company, announced that it has fully repaid and retired its $135,000 Non-Convertible inventory factoring credit facility, entered into with an institutional investor, on October 6, 2020.

Jaguar Health, Inc. announced the voting results of the Company’s May 13, 2021 Annual Meeting of Stockholders, which was adjourned until September 3, 2021.

Perrigo Company plc (NYSE; TASE: PRGO), today announced that Perrigo President and CEO, Murray S. Kessler, and CFO, Ray Silcock, are scheduled to participate in investor meetings at the Barclays Global Consumer Staples Conference on Thursday, September 9.

Amgen (NASDAQ:AMGN) will present at Citi’s 16th Annual BioPharma Conference at 1:25 p.m. ET on Wednesday, Sept. 8, 2021. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present at the conference.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 74,055 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of Atara’s common stock to five such newly hired employees.

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has submitted for a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that management will present at the following investor conferences during the month of September 2021.